ELITE PHARMACEUTICALS INC /NV/
Elite Pharmaceuticals is a specialty pharmaceutical company that develops and manufactures oral controlled-release products and manufactures generic pharmaceuticals. It sells and distributes generic medicines, develops additional products, and commercializes products through its own sales, licensing and royalties, or manufacturing for other companies. Its commercial products include medicines for pain, ADHD, cardiovascular conditions, bariatric use, and other therapeutic categories. Elite Labs, its wholly-owned subsidiary, distributes products sold under the Elite Labs label. Elite manufactures products at its Northvale Facility, which includes manufacturing, warehouse, laboratory and office space in Northvale, New Jersey. It also supplies products to partners for distribution, including Amphetamine IR Tablets for Dexcel in Israel; Dexcel handles sales, marketing and distribution and pays a transfer price, with profit sharing under specified conditions. Its development work includes generic drugs and abuse-deterrent opioid products.
No SEC Form 4 filings for $ELTP in the last 30 days.
See all $ELTP insider activity →Elite Pharmaceuticals (ELTP) will release its fiscal Q2 2027 results on Nov. 12 and host a conference call on Nov. 13 to discuss the results and provide a business update. Shareholders can submit questions before the call.
ELITE PHARMACEUTICALS INC /NV/ (ELTP) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter of Fiscal Year 2027 Financial Results on November 13, 2026 Financials for Second Quarter of Fiscal Year 2027 Ended September 30, 2026 will be released on Thursd
ELITE PHARMACEUTICALS INC /NV/ (ELTP) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Elite Pharmaceuticals Expands Board of Directors with Election of Aqeel A. Fatmi, Ph.D., and John W. LaRocca, Esq. Northvale, NJ – November 3, 2026: Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCQB: ELTP), a specialty pharmaceutical company developing ni
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning ELTP (ELITE PHARMACEUTICALS INC /NV/). Coverage has been balanced: 0 bullish, 2 neutral, and 0 bearish.
Recent ELTP coverage spans earnings, insider activity and financial news.
The earnings release is expected to drive short-term volatility as investors react to the disclosed results.
The announcement is informational with no immediate catalyst; price likely remains neutral until results are released.
The board expansion is a governance change with limited immediate market impact.
Small insider buy may signal confidence but size is modest.
Small insider purchase signals confidence but limited market impact.
AlphAI scores every news story that mentions ELTP with an AI model for sentiment and relevance, and aggregates insider trades from ELITE PHARMACEUTICALS INC /NV/'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Elite Pharmaceuticals (ELTP) will release its fiscal Q2 2027 results on Nov. 12 and host a conference call on Nov. 13 to discuss the results and provide a business update. Shareholders can submit questions before the call.
ELITE PHARMACEUTICALS INC /NV/ (ELTP) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter of Fiscal Year 2027 Financial Results on November 13, 2026 Financials for Second Quarter of Fiscal Year 2027 Ended September 30, 2026 will be released on Thursd
ELITE PHARMACEUTICALS INC /NV/ (ELTP) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Elite Pharmaceuticals Expands Board of Directors with Election of Aqeel A. Fatmi, Ph.D., and John W. LaRocca, Esq. Northvale, NJ – November 3, 2026: Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCQB: ELTP), a specialty pharmaceutical company developing ni
Dash Barry H purchased 100,000 shares of ELITE PHARMACEUTICALS INC /NV/ (ELTP) at $0.26 on 2026-10-09.
Dash Barry H purchased 30,000 shares of ELITE PHARMACEUTICALS INC /NV/ (ELTP) at $0.29 on 2026-08-19.
Elite Pharmaceuticals (ELTP) Q1 FY2027 earnings call said revenue and operating profit were lower year over year due to normalization after the initial Vyvanse generic launch. CFO cited rising volumes and a non-cash working capital drop from warrant reclassification. CEO discussed proposed generic drug tariffs, Nasdaq uplisting by about Feb 2027, and FDA issues affecting an Oxy ER launch timeline.
ELITE PHARMACEUTICALS INC /NV/ (ELTP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2027 ended June 30, 2026 and Provides Conference Call Information Conference Call Scheduled for Friday, August 14, 2026 at 11:30 AM EDT Northvale, NJ – August 13, 2026: Elite P
ELITE PHARMACEUTICALS INC /NV/ (ELTP) filed an SEC Form 8-K — Results of Operations and Financial Condition. false 0001053369 0001053369 2026-06-29 2026-06-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 June 29, 2026
